Literature DB >> 11679970

Defective mitogen-activated protein kinase (ERK2) signaling in gastric mucosa of portal hypertensive rats: potential therapeutic implications.

H Kawanaka1, M Tomikawa, M K Jones, I L Szabo, R Pai, D Baatar, K Tsugawa, K Sugimachi, I J Sarfeh, A S Tarnawski.   

Abstract

Portal hypertensive (PHT) gastropathy is a frequent, serious complication of liver cirrhosis. PHT gastric mucosa has numerous abnormalities such as reduced mucosal potential differences, reduced surface oxygenation, and increased susceptibility to injury caused by alcohol, aspirin, and other noxious factors. Because such mucosal injury is initially mediated by oxygen free radicals, and because mitogen-activated protein (MAP) kinase (ERK2) protects against cellular stress and induces cell proliferation, we postulated that oxidative stress-induced ERK2 activation is defective in PHT gastric mucosa. Here we show that in PHT gastric mucosa, ERK2 activation by oxidative stress is impaired. This impairment is mediated by overexpression of MAP kinase phosphatase-1 (MKP-1), which results from the underlying and continual oxidative state associated with portal hypertension, and is ameliorated by inhibiting MKP-1. Furthermore, we found that supplementing vitamin E, a free radical scavenger, reduces the oxidative state in PHT gastric mucosa, normalizes MKP-1 expression, and thereby reverses impairment of oxidative stress-induced ERK2 activation. Finally, we show that orally administered vitamin E completely reverses the increased susceptibility of PHT gastric mucosa to alcohol injury. Our findings point to a new molecular and mechanistic basis for PHT gastropathy and provide a new therapeutic modality for protection of PHT gastric mucosa.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11679970     DOI: 10.1053/jhep.2001.28507

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

2.  Activation of MEK 1/2 and p42/44 MAPK by angiotensin II in hepatocyte nucleus and their potentiation by ethanol.

Authors:  Annayya R Aroor; Youn Ju Lee; Shivendra D Shukla
Journal:  Alcohol       Date:  2009-06       Impact factor: 2.405

Review 3.  Management of gastropathy and gastric vascular ectasia in portal hypertension.

Authors:  Cristina Ripoll; Guadalupe Garcia-Tsao
Journal:  Clin Liver Dis       Date:  2010-05       Impact factor: 6.126

Review 4.  Portal hypertensive gastropathy and colopathy.

Authors:  Nathalie H Urrunaga; Don C Rockey
Journal:  Clin Liver Dis       Date:  2014-05       Impact factor: 6.126

5.  Helicobacter pylori Infection in Cirrhotic Patients With Portal Hypertensive Gastropathy: A New Enigma?

Authors:  Sumaiah J Alarfaj; Sally Abdallah Mostafa; Ramy A Abdelsalam; Walaa A Negm; Thanaa A El-Masry; Ismail A Hussein; Ahmed Mohamed El Nakib
Journal:  Front Med (Lausanne)       Date:  2022-06-17

Review 6.  Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.

Authors:  Sasidharan Rajesh; Tom George; Cyriac Abby Philips; Rizwan Ahamed; Sandeep Kumbar; Narain Mohan; Meera Mohanan; Philip Augustine
Journal:  World J Gastroenterol       Date:  2020-10-07       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.